Aastrom Biosciences to Hold Investor Conference Call
May 03 2005 - 9:02AM
PR Newswire (US)
Aastrom Biosciences to Hold Investor Conference Call ANN ARBOR,
Mich., May 3 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc.
(NASDAQ:ASTM) announced today that it will host an investor
conference call on Friday, May 6, 2005 at 11:00 a.m. (ET).
Aastrom's call will begin with brief presentations by R. Douglas
Armstrong, Ph.D., Chief Executive Officer and Chairman, and Alan M.
Wright, Senior Vice President Administrative & Financial
Operations and Chief Financial Officer. The balance of the call
will be devoted to questions from registered callers. Interested
parties should call (785) 832-0326, or toll-free (877) 707- 9628,
fifteen minutes before the start of the call and identify
themselves as registrants of the 'Aastrom Conference Call'. The
call will be simulcast on the web at
http://phx.corporate-ir.net/playerlink.zhtml?c=85924&s=wm&e=1054502,
and archived for 90 days at the same site. About Aastrom
Biosciences, Inc. Aastrom Biosciences, Inc. (NASDAQ:ASTM) is
developing patient-specific products for the repair or regeneration
of human tissues, utilizing the Company's proprietary adult stem
cell technology. Aastrom's strategic position in the tissue
regeneration sector is enabled by its proprietary Tissue Repair
Cells (TRCs), a mix of bone marrow-derived adult stem and
progenitor cells, and the AastromReplicell(R) System, an
industry-unique automated cell production platform used to produce
cells for clinical use. TRCs are the core component of the products
Aastrom is developing for severe bone fractures, ischemic vascular
disease, jaw reconstruction and spine fusion, with Phase I/II level
clinical trials active in the U.S. and EU for some of these
indications. For more information, visit Aastrom's website at
http://www.aastrom.com/. This document contains forward-looking
statements, including without limitation, statements concerning
planned clinical trials, product development objectives, potential
product applications, and potential advantages of the
AastromReplicell(R) System, which involve certain risks and
uncertainties. The forward-looking statements are also identified
through use of the word "plan," and other words of similar meaning.
Actual results may differ significantly from the expectations
contained in the forward-looking statements. Among the factors that
may result in differences are clinical trial results, potential
product development difficulties, the effects of competitive
therapies, regulatory approval requirements, the availability of
financial and other resources and the allocation of resources among
different potential uses. These and other significant factors are
discussed in greater detail in Aastrom's Annual Report on Form 10-K
and other filings with the Securities and Exchange Commission.
CONTACTS: Kris M. Maly or Kevin McGrath Becky Anderson Cameron
Associates Investor Relations Department Phone: (212) 245-4577
Aastrom Biosciences, Inc. Phone: (734) 930-5777 DATASOURCE: Aastrom
Biosciences, Inc. CONTACT: Kris M. Maly or Becky Anderson, Investor
Relations Department of Aastrom Biosciences, Inc., +1-734-930-5777;
or Kevin McGrath of Cameron Associates, +1-212-245-4577 Web site:
http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024